Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 27/09/19 at 12:55pm

Another week comes to a close, and it's time to review the biggest stories of the week. Check out the ten most popular articles on Pharamfile.com over the past seven days below:

10. Bluebird bio's Lenti-D gene therapy shows promise in cerebral adrenoleukodystrophy

Bluebird bio has revealed updated data for its investigational Lenti-D gene therapy in the treatment of cerebral adrenoleukodystrophy (CALD), a rare genetic and rapidly progressive disease that carries the threat of severe loss of neurologic function and death, a the 13th European Pediatric Neurology Society (EPNS) Congress in Athens.

9. Bayer's Vitravki becomes first EU-approved tumour-agnostic therapy

Bayer has announced that its tyrosine receptor kinase (TRK) inhibitor Vitrakvi (larotrectinib) has scored approval from the European Commission for the treatment of locally advanced or metastatic solid tumours with an NTRK gene fusion in adult and paediatric patients who have no satisfactory treatment options, or for whom surgical resection is likely to result in severe morbidity.

8. Antidepressant sertraline works ‘by reducing anxiety symptoms first’

Researchers at University College London have found that a commonly prescribed antidepressant, sertraline, works in unexpected ways, first relieving users of anxiety and then having a smaller effect on depressive symptoms weeks later.

7. Biogen to start new Spinraza trial to preserve market share

Biogen is planning a new trial of $1.7billion-a-year Spinraza to investigate much higher doses in spinal muscular atrophy (SMA) and thwart off competition from new player Zolgensma from Novartis.

6. EMA’s CHMP recommends three new medications

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) have recommended approval for three new medicines with AstraZeneca securing approval from regulators to market its Qtrilmet tablets for the treatment of type 2 diabetes.

5. NICE shoots down Novartis' migraine drug Aimovig outside of Scotland

NICE has announced its decision to reject Novartis’ drug Aimovig (erenumab) for use on the NHS in England and Wales for the prevention of chronic and episodic migraine in adult patients who experience at least four episodes of migraine a month.

4. Iran reveals plans to domestically produce 135 strategic drugs

Iran has announced plans to promote self-sufficiency within the country with regard to its medicines production, with an aim of producing 135 strategic pharmaceutical products within its borders.

3. FDA approves Novo’s new type 2 diabetes pill

A new drug from Danish drug maker Novo Nordisk, called Rybelsus (semaglutide), has been approved by the FDA for the use in patients with type 2 diabetes to lower blood sugar levels.

2. Lundbeck and Takeda's depression drug approved in Japan

Takeda and Lundbeck have announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has chosen to authorise their drug Trintellix (vortioxetine) for the treatment of major depressive disorder, described in the companies’ press release as “depression and depressed state”.

1. Servier on trial for weight-loss pill that led to 2,000 deaths

A trial on one of France’s largest ever healthcare scandals has begun after a weight loss pill was believed to have killed up to 2,000 people, leaving many more injured for life.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches